Microcap March Madness: LNAI, FAGI, VSA, LNKS Sweet 16 Underdogs to Watch Getting your Trinity Audio player ready... A new wave of activity across biotech innovation, artificial intelligence, digital infrastructure, and global manufacturing is drawing increased investor att...

Microcap March Madness: #LNAI, #FAGI, #VSA, #LNKS Sweet 16 Underdogs to Watch

thestreetreports.com/microcap-mar...

Microcap March Madness: LNAI, FAGI, VSA, LNKS Sweet 16 Underdogs to Watch Getting your Trinity Audio player ready... A new wave of activity across biotech innovation, artificial intelligence, digital infrastructure, and global manufacturing is drawing increased investor att...

New wave of activity across biotech innovation, artificial intelligence, digital infrastructure, & global manufacturing
thestreetreports.com/microcap-mar...
#FAGI #VSA #LNKS #LNAI

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI) launched the Pathfinder Consortium on March 19, 2026, a national academic–industry alliance to accelerate chemical countermeasure discovery and federal stockpiling.The consortium aims to compress countermeasure development to ~36 months and target U.S. procurement programs sized between $400M and $1.2B per program, leveraging BioSymetrics' AI phenotypic platform and multi‑partner execution.

#LNAI Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time.. SACRAMENTO, Calif., Jan. 27, 2026/ PRNewswire/-- As global attention intensifies around the dual-use risks of advanced artificial...

#LNAI Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery Lunai Bioworks (NASDAQ: LNAI) completed an NIH STTR commercial milestone creating high-resolution, multidimensional behavioral signatures of ethanol exposure and withdrawal and has launched a commercial Alcohol Use Disorder (AUD) drug-discovery program.The program uses scalable high-throughput vertebrate screening, targets underexplored mechanisms, is supported by NIH funding, and is run in collaboration with Dr. Calum MacRae at Brigham and Women's Hospital/Harvard Medical School.Company cites a large unmet need: ~30 million U.S. individuals affected, ~95% receiving no effective pharmacologic treatment, and a ~$250 billion annual economic cost.

#LNAI Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance SACRAMENTO, Calif., Dec. 18, 2025/ PRNewswire/-- Lunai Bioworks Inc., an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end analysis highlighting the company's strategic positioning, active partnership discussions, and favorable market dynamics as 2025 draws to a close. The International Business Times...

#LNAI Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.Analysis integrated longitudinal clinical and proteomic data from >650 participants and ~4,500 proteomic probes (median follow-up ≥2.5 years), linking subtypes to rapid progression, cognitive decline, and functional impairment. Lunai is initiating experimental validation, preclinical model development, and biomarker qualification while evaluating co-development opportunities in a market projected to exceed $13 billion by the 2030s.

#LNAI Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models Lunai Bioworks (NASDAQ: LNAI) announced it has secured a first letter of intent (LOI) to license its next‑generation dendritic cell combination therapy (DCCT) after peer‑reviewed publication and independent expert review. In humanized mouse models of pancreatic cancer, the DCCT produced complete regression of primary and metastatic tumors with no recurrence and 80–90% tumor size reduction across two studies. Lunai also reported a successful pre‑IND meeting with the FDA and plans for formal licensing negotiations and pre‑IND activities in early 2026 toward a proposed Phase I trial for high‑need solid tumors.

#LNAI Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

www.stocktitan.net/news/LNAI/lunai-bioworks...

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds Lunai Bioworks (NASDAQ:LNAI) announced early results from an AI-driven platform that identifies compounds interacting with acetylcholinesterase (AChE), the molecular target of nerve agents. The company reported its predictive model achieved 0.94 AUROC for distinguishing active AChE inhibitors from inactive compounds and flagged previously unidentified candidate neurotoxic compounds for follow-up. Lunai plans to combine the AI predictions with behavioral zebrafish profiling to observe real-time physiological effects and prioritize countermeasures. The company also embedded the model in a partner dashboard to enable collaborative chemical-structure screening for potential neurotoxicity.

#LNAI Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

www.stocktitan.net/news/LNAI/lunai-bioworks...

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics Lunai Bioworks (NASDAQ:LNAI) subsidiary BioSymetrics and academic partners published a Nature Communications study (Oct 16, 2025) reporting prognostic serum protein biomarkers for Duchenne muscular dystrophy (DMD).The multi‑institutional analysis used the SomaScan proteomics platform on >700 longitudinal serum samples from European and U.S. cohorts and identified proteins including RGMA, ART3, and ANTXR2 that associate with motor performance and predict outcomes such as loss of ambulation and upper‑limb decline.Authors say these minimally invasive biomarkers could refine clinical trial enrollment, improve stratification, and support more personalized patient management, while results were cross‑cohort validated and controlled for age and corticosteroid use.

#LNAI Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

www.stocktitan.net/news/LNAI/landmark-study...

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company

#LNAI Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

www.stocktitan.net/news/LNAI/lunai-bioworks...

AI Drug Discovery Pioneer Lunai Bioworks Emerges with New Identity and Streamlined 23.2M Share Structure Biotech firm rebrands as Lunai Bioworks, reduces shares from 231.8M to 23.2M via reverse split. Launches transformer-based AI platform for neurotoxicity and advances Parkinson's biomarker program.

#LNAI Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

www.stocktitan.net/news/LNAI/lunai-bioworks...